Reduced replication of 3TC-resistant HIV-1 variants in primary cells due to a processivity defect of the reverse transcriptase enzyme - PubMed (original) (raw)

. 1996 Aug 1;15(15):4040-9.

Affiliations

PMID: 8670908
PMCID: PMC452124

Reduced replication of 3TC-resistant HIV-1 variants in primary cells due to a processivity defect of the reverse transcriptase enzyme

N K Back et al. EMBO J. 1996.

Abstract

Human immunodeficiency virus type 1 (HIV-1) variants with resistance mutations in the reverse transcriptase (RT) gene appear during drug therapy with the nucleoside analogue 2',3'-dideoxy-3'-thiacytidine (3TC). These resistance mutations alter the methionine (Met) residue of the conserved YMDD motif, which is part of the catalytic core of the RT enzyme. Isoleucine (Ile) variants are initially observed, followed by the appearance and eventual outgrowth of viruses encoding valine (Val). Similar replication kinetics were measured for wild-type and 3TC-resistant HIV-1 viruses in tissue culture infections of a T cell line, but we measured reduced polymerase activity for the two mutant RT enzymes compared with the wild-type enzyme (Ile = 43% and Val = 67%). Gel analysis of the reverse transcription products revealed that both 3TC-resistant RT mutants produce significantly shorter cDNA molecules than the wild-type enzyme [Met (wt)>Val>Ile], indicating that 3TC-resistant RT polymerases are less processive enzymes. Interestingly, these enzyme defects were more pronounced under limiting dNTP concentrations and we therefore assayed virus replication in primary cells that contain relatively low dNTP levels. Under these conditions, we measured significantly reduced replication kinetics for the 3TC-resistant HIV-1 variants [Met (wt)>Val>Ile]. If the level of virus replication can be similarly reduced in 3TC-treated patients that develop drug-resistant HIV-1 variants, this may be of considerable clinical benefit.

PubMed Disclaimer

Cited by

Multiple effects of the M184V resistance mutation in the reverse transcriptase of human immunodeficiency virus type 1.
Turner D, Brenner B, Wainberg MA. Turner D, et al. Clin Diagn Lab Immunol. 2003 Nov;10(6):979-81. doi: 10.1128/cdli.10.6.979-981.2003. Clin Diagn Lab Immunol. 2003. PMID: 14607855 Free PMC article. Review. No abstract available.
Dynamics of HIV-1 quasispecies during antiviral treatment dissected using ultra-deep pyrosequencing.
Hedskog C, Mild M, Jernberg J, Sherwood E, Bratt G, Leitner T, Lundeberg J, Andersson B, Albert J. Hedskog C, et al. PLoS One. 2010 Jul 7;5(7):e11345. doi: 10.1371/journal.pone.0011345. PLoS One. 2010. PMID: 20628644 Free PMC article.
The 5' and 3' TAR elements of human immunodeficiency virus exert effects at several points in the virus life cycle.
Das AT, Klaver B, Berkhout B. Das AT, et al. J Virol. 1998 Nov;72(11):9217-23. doi: 10.1128/JVI.72.11.9217-9223.1998. J Virol. 1998. PMID: 9765469 Free PMC article.
Limiting deoxynucleoside triphosphate concentrations emphasize the processivity defect of lamivudine-resistant variants of human immunodeficiency virus type 1 reverse transcriptase.
Back NK, Berkhout B. Back NK, et al. Antimicrob Agents Chemother. 1997 Nov;41(11):2484-91. doi: 10.1128/AAC.41.11.2484. Antimicrob Agents Chemother. 1997. PMID: 9371354 Free PMC article.

References

1. Antimicrob Agents Chemother. 1990 Mar;34(3):436-41 - PubMed
1. J Virol. 1990 Jun;64(6):2660-8 - PubMed
1. AIDS Res Hum Retroviruses. 1995 Oct;11(10):1149-51 - PubMed
1. Science. 1996 Mar 1;271(5253):1282-5 - PubMed
1. J Virol. 1994 Mar;68(3):1581-5 - PubMed

Reduced replication of 3TC-resistant HIV-1 variants in primary cells due to a processivity defect of the reverse transcriptase enzyme - PubMed (original) (raw)